FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
February 17 2023 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and
full year 2022 financial results on Monday, February 27 after the
market close. FibroGen will also conduct a conference call on that
day at 5:00 PM Eastern Time with the investment community to
further detail the company's corporate and financial performance.
Conference Call and Audio Webcast Interested
parties may access a live audio webcast of the conference call via
the “Investor Relations” page of the Company’s website at
www.fibrogen.com. To access the call by phone, please go to this
link (registration link), and you will be provided with dial in
details. To avoid delays, we encourage participants to dial into
the conference call fifteen minutes ahead of the scheduled start
time. A replay of the webcast will also be available for a limited
time at the following link (webcast replay).
About FibroGen FibroGen, Inc. is a
biopharmaceutical company committed to discovering, developing, and
commercializing a pipeline of first-in-class therapeutics. The
Company applies its pioneering expertise in connective tissue
growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to
advance innovative medicines for the treatment of unmet needs.
Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical
development for the treatment of idiopathic pulmonary fibrosis
(IPF), locally advanced unresectable pancreatic cancer (LAPC),
metastatic pancreatic cancer, and Duchenne muscular dystrophy
(DMD). Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China,
Europe, Japan, and numerous other countries for the treatment of
anemia in CKD patients on dialysis and not on dialysis. Roxadustat
is in Phase 3 clinical development in the U.S. and Europe for
anemia associated with myelodysplastic syndromes (MDS), and in
Phase 3 clinical development in China for treatment of
chemotherapy-induced anemia (CIA). FibroGen recently expanded its
research and development portfolio to include product candidates in
the immuno-oncology and autoimmune space. For more information,
please visit www.fibrogen.com.
Contacts: FibroGen, Inc.
Investors:Michael Tung, M.D.Corporate Strategy
/ Investor Relations1.415.978.1434mtung@fibrogen.com
Media:Meichiel KeenanInvestor Relations and
Corporate Communicationsmkeenan@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024